DK0935609T3 - Krystalliserbare præparater omfattende et hepatitis-C-virus-NS3-proteasedomæne/NS4A-kompleks og dermed opnåede krystaller - Google Patents

Krystalliserbare præparater omfattende et hepatitis-C-virus-NS3-proteasedomæne/NS4A-kompleks og dermed opnåede krystaller

Info

Publication number
DK0935609T3
DK0935609T3 DK97942450T DK97942450T DK0935609T3 DK 0935609 T3 DK0935609 T3 DK 0935609T3 DK 97942450 T DK97942450 T DK 97942450T DK 97942450 T DK97942450 T DK 97942450T DK 0935609 T3 DK0935609 T3 DK 0935609T3
Authority
DK
Denmark
Prior art keywords
hepatitis
virus
crystallizable
preparations
obtained crystals
Prior art date
Application number
DK97942450T
Other languages
Danish (da)
English (en)
Inventor
Joseph L Kim
Kurt A Morgenstern
Chao Lin
Ted Fox
John A Thomson
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Application granted granted Critical
Publication of DK0935609T3 publication Critical patent/DK0935609T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional [2D] or three-dimensional [3D] molecular structures, e.g. structural or functional relations or structure alignment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Materials Engineering (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Metallurgy (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK97942450T 1996-09-12 1997-09-12 Krystalliserbare præparater omfattende et hepatitis-C-virus-NS3-proteasedomæne/NS4A-kompleks og dermed opnåede krystaller DK0935609T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2527496P 1996-09-12 1996-09-12
US08/731,336 US6153579A (en) 1996-09-12 1996-10-18 Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex
PCT/US1997/016182 WO1998011134A1 (en) 1996-09-12 1997-09-12 Crystallizable compositions comprising a hepatitis c virus ns3 protease domain/ns4a complex and crystals thereby obtained

Publications (1)

Publication Number Publication Date
DK0935609T3 true DK0935609T3 (da) 2002-07-22

Family

ID=26699520

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97942450T DK0935609T3 (da) 1996-09-12 1997-09-12 Krystalliserbare præparater omfattende et hepatitis-C-virus-NS3-proteasedomæne/NS4A-kompleks og dermed opnåede krystaller

Country Status (12)

Country Link
US (2) US6153579A (enExample)
EP (1) EP0935609B1 (enExample)
JP (1) JP2001501602A (enExample)
AT (3) ATE244729T1 (enExample)
AU (1) AU736857B2 (enExample)
CA (1) CA2264964A1 (enExample)
DE (3) DE69712085T2 (enExample)
DK (1) DK0935609T3 (enExample)
ES (2) ES2202228T3 (enExample)
IL (1) IL128826A0 (enExample)
PT (2) PT1118619E (enExample)
WO (1) WO1998011134A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ335276A (en) 1996-10-18 2000-09-29 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus (HCV) NS3 (Non Structural Protein 3) protease
IL143798A0 (en) 1999-01-08 2002-04-21 Bristol Myers Squibb Co Hepatitis c virus ns3 protease
US6524589B1 (en) * 1999-04-08 2003-02-25 Schering Corporation Compositions of hepatitis C virus NS3/NS4A complex and methods for crystallizing same
JP2003511467A (ja) 1999-10-14 2003-03-25 ブリストル−マイヤーズ スクイブ カンパニー アンドロゲンレセプターリガンド結合ドメインの結晶構造
US7491808B2 (en) 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
HUP0303172A3 (en) 2000-06-28 2006-05-29 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, desing and use
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP1334179A2 (en) 2000-11-14 2003-08-13 Bristol-Myers Squibb Company A human serpin secreted from lymphoid cells lsi-01
CA2443393A1 (en) 2001-04-03 2002-11-07 Bristol-Myers Squibb Company Polynucleotide encoding a novel cysteine protease of the calpain superfamily, can-12, and variants thereof
US20030027315A1 (en) * 2001-09-24 2003-02-06 Ada Yonath Methods of growing crystals of free and antibiotic complexed large ribosomal subunits, and methods of rationally designing or identifying antibiotics using structure coordinate data derived from such crystals
US20050009877A1 (en) * 2003-05-15 2005-01-13 Henry Lu Methods of identifying HCV NS5B polymerase inhibitors and their uses
MY148123A (en) 2003-09-05 2013-02-28 Vertex Pharma Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
ES2389201T3 (es) 2003-10-27 2012-10-24 Vertex Pharmaceuticals Incorporated Mutantes de resistencia de la proteasa NS3/4A de HCV
WO2005043118A2 (en) 2003-10-27 2005-05-12 Vertex Pharmaceuticals Incorporated Drug discovery method
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
NZ568324A (en) 2005-11-11 2012-01-12 Vertex Pharma Hepatitis C virus variants
EP1991229A2 (en) 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
JP2009531315A (ja) * 2006-03-16 2009-09-03 バーテックス ファーマシューティカルズ インコーポレイテッド 重水素化c型肝炎プロテアーゼインヒビター
US8440443B1 (en) 2006-05-16 2013-05-14 Merck Sharp & Dohme Corp. MEK1 polypeptides
EA200970806A1 (ru) 2007-02-27 2010-08-30 Вертекс Фармасьютикалз Инкорпорейтед Сокристаллы и содержащие их фармацевтические композиции
US8575208B2 (en) 2007-02-27 2013-11-05 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
EP2436682A1 (en) 2007-08-30 2012-04-04 Vertex Pharmceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US8988881B2 (en) * 2007-12-18 2015-03-24 Sandia Corporation Heat exchanger device and method for heat removal or transfer
US9005417B1 (en) 2008-10-01 2015-04-14 Sandia Corporation Devices, systems, and methods for microscale isoelectric fractionation
US9795961B1 (en) 2010-07-08 2017-10-24 National Technology & Engineering Solutions Of Sandia, Llc Devices, systems, and methods for detecting nucleic acids using sedimentation
US9261100B2 (en) 2010-08-13 2016-02-16 Sandia Corporation Axial flow heat exchanger devices and methods for heat transfer using axial flow devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4833233A (en) * 1987-08-20 1989-05-23 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Human serum albumin crystals and method of preparation
US5353236A (en) * 1992-04-23 1994-10-04 The Board Of Trustees Of The Leland Stanford University High-resolution crystallographic modelling of a macromolecule
US5453937A (en) * 1993-04-28 1995-09-26 Immunex Corporation Method and system for protein modeling
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.

Also Published As

Publication number Publication date
US6153579A (en) 2000-11-28
IL128826A0 (en) 2000-01-31
US6303287B1 (en) 2001-10-16
ES2202228T3 (es) 2004-04-01
CA2264964A1 (en) 1998-03-19
DE69712085T2 (de) 2002-11-28
JP2001501602A (ja) 2001-02-06
AU4414597A (en) 1998-04-02
WO1998011134A1 (en) 1998-03-19
DE69736995D1 (de) 2007-01-04
DE69736995T2 (de) 2007-09-20
ES2175462T3 (es) 2002-11-16
HK1038573A1 (en) 2002-03-22
EP0935609B1 (en) 2002-04-17
ATE216400T1 (de) 2002-05-15
DE69723485D1 (de) 2003-08-14
EP0935609A1 (en) 1999-08-18
AU736857B2 (en) 2001-08-02
ATE346088T1 (de) 2006-12-15
DE69712085D1 (de) 2002-05-23
HK1022700A1 (en) 2000-08-18
PT935609E (pt) 2002-09-30
ATE244729T1 (de) 2003-07-15
PT1118619E (pt) 2003-11-28
DE69723485T2 (de) 2004-05-27

Similar Documents

Publication Publication Date Title
PT935609E (pt) Composicoes cristalizaveis que contem um complexo entre o dominio de protease ns3 do virus da hepatite c e ns4a cristais resultantes
DE60144145D1 (de) Subtilisin-variante
FI935808A0 (fi) Hepatit-C-virus (HCV) polypeptider
FI941199A0 (fi) Immunoreaktiiviset hepatiitti-C-viruksen polypeptidikoostumukset
ITRM940092A0 (it) Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
ATE212037T1 (de) Inhibitoren von serinproteasen, insbesondere von ns3-protease des hepatitis-c-virus
AU1416099A (en) Single-chain recombinant complexes of hepatitis c virus ns3 protease and ns4a cofactor peptide
NZ503263A (en) Hepatitis C NS3 protease inhibitor peptides and peptide analogues
DK0754704T3 (da) Syntetiske antigener til påvisning af antistoffer mod hepatitis c-virus
ATA117890A (de) Komplexes virales antigen von hiv-1 bindendes rekombinantes protein
DK0996409T3 (da) Præparat til at forsinke hårvækst og tilsvarende anvendelse
DE69232906D1 (de) Detektion des Hepatis-C Virus.
ATE163013T1 (de) Alveolare oberflächenaktive proteine
DE68917837D1 (de) Peptid-Verbindungen.
ATE308618T1 (de) Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen
ATE109158T1 (de) Rubella-e1 und c peptide.
DE69106141D1 (de) Non-a non-b sequenzen.
DK1417233T3 (da) Humant rekombinant antistof mod det hepatitis C (HCV) ikke-strukturelle NS3-protein, nukleinsyre og anvendelser deraf
DK196689D0 (da) Ekspression af praes2-proteinet for hepatitis b i methylotrophe gaerarter
DE60034243D1 (de) Rekombinante bifunktionale fusionsproteine zur abtreibung variabler viren
IT1270941B (it) Peptidi di hcv e loro usi.
EP1310512A3 (en) Hcv core protein sequences
SE9604439D0 (sv) New receptor
WO2004089978A3 (en) Use of hcv proteins